Trimetazidine


Generic Medicine Info
Indications and Dosage
Oral
Stable angina
Adult: As adjunctive therapy for symptomatic treatment of patients who are inadequately controlled by or intolerant to first-line antianginal therapies: Conventional tab: 20 mg tid. Modified-release tab: 35 mg bid.
Renal Impairment
CrCl (mL/min) Dosage
<30 Contraindicated.
30-60 Conventional tab: 20 mg bid. Modified-release tab: 35 mg once daily.
Administration
Should be taken with food.
Contraindications
Parkinson's disease, parkinsonian symptoms, tremors, restless leg syndrome and other movement related disorders. Severe renal impairment (CrCl <30 mL/min). Lactation.
Special Precautions
Moderate renal impairment. Elderly. Pregnancy. Not indicated for initial treatment of unstable angina, myocardial infarction nor in the pre-hospital phase or during the first days of hospitalisation.
Adverse Reactions
Significant: Movement disorders (e.g. Parkinsonian symptoms, restless leg syndrome, tremors, gait instability).
Gastrointestinal disorders: Abdominal pain, dyspepsia, diarrhoea, nausea and vomiting.
General disorders and admin site conditions: Asthenia.
Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria.
Vascular disorders: Rarely, arterial hypotension, orthostatic hypotension.
Patient Counseling Information
This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery.
Action
Description: Trimetazidine inhibits β-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, thereby enhancing glucose oxidation. By preserving energy metabolism in cells exposed to ischaemia or hypoxia, it prevents decrease in intracellular ATP levels and ensures proper functioning of ionic pumps and transmembrane Na-K flow.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: <2 hours (immediate-release); approx 5 hours (modified-release).
Distribution: Volume of distribution: 4.8 L/kg. Plasma protein binding: 16%.
Excretion: Via urine, mainly as unchanged drug. Elimination half-life: Approx 6 hours (immediate-release); approx 7 hours (modified-release).
Chemical Structure

Chemical Structure Image
Trimetazidine

Source: National Center for Biotechnology Information. PubChem Database. Trimetazidine, CID=21109, https://pubchem.ncbi.nlm.nih.gov/compound/Trimetazidine (accessed on Jan. 23, 2020)

Storage
Store below 30°C.
MIMS Class
ATC Classification
C01EB15 - trimetazidine ; Belongs to the class of other cardiac preparations.
References
Anon. Trimetazidine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 28/10/2015.

Buckingham R (ed). Trimetazidine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 14/08/2019.

Matenol MR (Unison). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 15/08/2019.

Vastarel MR. MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 28/10/2015.

Whilst Modified-release tablet (The Acme Laboratories Ltd.). MIMS Philippines. http://www.mims.com/philippines. Accessed 15/08/2019.

Disclaimer: This information is independently developed by MIMS based on Trimetazidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
  • Metagem
  • Trizidine
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in